Greetings
Summary:
Fundamental Analysis:
Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019
Company expects top-line results from one of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis by the end of 2021
In April 2021, the Company expects to initiate a randomized, proof of...
Greetings
Summary:
Fundamental Analysis:
Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative.Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies
Fluidigm is a leader in mass cytometry....
